Scribe Therapeutics (NASDAQ:SCTX) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Scribe Therapeutics (NASDAQ:SCTX) in a research report report published on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $60.00 price objective on the stock. HC Wainwright also issued estimates for Scribe Therapeutics’ Q2 2026 earnings at ($6.20) EPS, Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.05) EPS, FY2026 earnings at ($6.72) EPS, Q1 2027 earnings at ($1.10) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.36) EPS and FY2027 earnings at ($4.90) EPS.

A number of other equities research analysts also recently commented on SCTX. Leerink Partners began coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective for the company. Guggenheim assumed coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen raised Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. Finally, Wells Fargo & Company started coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 target price for the company. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, Scribe Therapeutics has a consensus rating of “Buy” and an average target price of $51.75.

Scribe Therapeutics Stock Performance

SCTX stock opened at $30.90 on Monday. Scribe Therapeutics has a 12 month low of $17.31 and a 12 month high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX) last posted its quarterly earnings results on Wednesday, September 2nd. The company reported ($3.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.20) by $2.36. On average, sell-side analysts expect that Scribe Therapeutics will post -6.72 EPS for the current fiscal year.

Insider Transactions at Scribe Therapeutics

In other news, Director Behzad Aghazadeh bought 7,905 shares of the stock in a transaction on Tuesday, July 28th. The shares were purchased at an average price of $18.25 per share, for a total transaction of $144,266.25. Following the completion of the purchase, the director directly owned 3,088,888 shares of the company’s stock, valued at $56,372,206. This trade represents a 0.26% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bio Fund Ii L.P. Ah bought 333,333 shares of the stock in a transaction on Monday, July 27th. The stock was purchased at an average price of $15.00 per share, for a total transaction of $4,999,995.00. Following the purchase, the insider directly owned 2,385,075 shares of the company’s stock, valued at approximately $35,776,125. This represents a 16.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 3,727,237 shares of company stock worth $56,291,746 in the last ninety days.

Key Stories Impacting Scribe Therapeutics

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Quarterly loss beat expectations: Scribe reported a second-quarter 2026 loss of $3.84 per share, significantly narrower than the $6.20 loss analysts expected. The earnings surprise may have improved sentiment toward the clinical-stage biotechnology company. Scribe Therapeutics earnings press release
• Positive Sentiment: Pipeline advanced into human testing: The company initiated the first-in-human Phase 1 trial of STX-1150, an ultra-long-acting LDL-cholesterol-lowering therapy using its ELXR epigenetic silencing technology. The treatment is designed to avoid permanent genetic changes, potentially strengthening Scribe’s cardiovascular disease pipeline. Scribe Therapeutics second-quarter results and corporate highlights
• Positive Sentiment: Non-dilutive support and financing improved runway: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400. In addition, its upsized IPO, including the underwriters’ full option exercise, and a private placement to Sanofi generated approximately $155.5 million in gross proceeds. Management said available funding should support operations into the first half of 2029. Scribe Therapeutics financing and financial results
• Positive Sentiment: Analyst coverage was bullish: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the stock’s recent trading level. The firm projects continued losses but expects quarterly losses to narrow after 2026.
• Neutral Sentiment: Management also announced participation in upcoming investor conferences, which could provide additional visibility for Scribe’s technology and clinical programs but does not itself change the company’s fundamentals. Scribe Therapeutics investor conference announcement
• Negative Sentiment: Scribe remains unprofitable, with HC Wainwright forecasting a $6.72 per-share loss for fiscal 2026 and a $4.90 loss for fiscal 2027. Continued clinical spending and the recently issued equity could also create ongoing dilution and volatility risks.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.